AIM ImmunoTech Discusses Ampligen Pancreatic Strategy, Eyes Q1 2027 Phase 2 Topline

AIM ImmunoTech Inc. provided an update on Ampligen's potential role in pancreatic cancer, citing survival observations. The company expects topline results for its DURIPANC Phase 2 trial in Q1 2027, with an overall survival analysis to commence in 2027.